The Gut Microbiome and Treatment-Resistance in Schizophrenia

  title={The Gut Microbiome and Treatment-Resistance in Schizophrenia},
  author={Mary V. Seeman},
  journal={Psychiatric Quarterly},
  • M. Seeman
  • Published 2019
  • Medicine
  • Psychiatric Quarterly
The effect of antipsychotic medication is poor in 30–40% of patients with schizophrenia; treatment resistance is usually met with shifts to new drugs or drug augmentation strategies or a trial of clozapine. The purpose of this review was to examine the potential role of intestinal bacteria in the bioavailability of antipsychotic medication and the possibility that parenterally administered antipsychotics might be able to overcome treatment resistance. Databases were searched with appropriate… Expand

Paper Mentions

The gut microbiome and antipsychotic treatment response
  • M. Seeman
  • Medicine
  • Behavioural Brain Research
  • 2021
The aim of this review is to explore the potential role of intestinal organisms in response/non-response to antipsychotics and the modification of factors that, together, are known to determine the composition of microbiota. Expand
The Microbiota/Microbiome and the Gut–Brain Axis: How Much Do They Matter in Psychiatry?
Gut microbiota might represent an interesting field of research for a better understanding of the pathophysiology of common neuropsychiatric disorders and possibly as a target for the development of innovative treatments that some authors have already labelled “psychobiotics”. Expand
Comparative Efficacy and Safety of Long-acting Injectable and Oral Second-generation Antipsychotics for the Treatment of Schizophrenia: A Systematic Review and Meta-analysis
  • Seon-Cheol Park, M. Choi, +10 authors Seung-Hwan Lee
  • Medicine
  • Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology
  • 2018
There is moderate to high level of evidence suggesting that in the treatment of schizophrenia, LAI SGAs have higher efficacy and are associated with higher rates of extrapyramidal syndrome and prolactin-related symptoms. Expand
Reducing the stigma of long acting injectable antipsychotics – current concepts and future developments
The rationale for using LAI-APs is explained, their effectiveness is reviewed, barriers to use are explored and drug adherence remains a major target for improving treatment outcomes. Expand


Drug–gut microbiota interactions: implications for neuropharmacology
The relationship between drugs and the Gut microbiome is explored, with a specific focus on potential mechanisms underpinning the drug‐mediated alterations on the gut microbiome and the potential implications for psychoactive drugs. Expand
The Pharmacogenetics of Symptom Response to Antipsychotic Drugs
There is little consistency between various studies, although some of the polymorphisms identified are in genes involved in neurodevelopment, which is increasingly being recognized as important in the pathophysiology of schizophrenia. Expand
Second-generation antipsychotics and metabolism alterations: a systematic review of the role of the gut microbiome
Whether SGAs drive dysbiosis, whether gut microbiota alterations affect body weight and metabolic outcomes, and the possible mechanism of metabolic disturbances secondary to SGA treatment in animal and human studies are investigated. Expand
Psychotropics and the Microbiome: a Chamber of Secrets…
This review will take into consideration different classes of psychotropics including antipsychotics, antidepressants, antianxiety drugs, anticonvulsants/mood stabilisers, opioid analgesics, drugs of abuse, alcohol, nicotine and xanthines. Expand
Extensive impact of non-antibiotic drugs on human gut bacteria
A few commonly used non-antibiotic drugs have recently been associated with changes in gut microbiome composition, but the extent of this phenomenon is unknown. Here, we screened more than 1,000Expand
Intranasal delivery of antipsychotic drugs
If limitations of low aqueous solubility of antipsychotic drugs can be overcome and non-toxic formulations used, IN delivery will gain more importance moving forward given the inherent benefits of IN delivery in comparison to other methods. Expand
D2 receptor genetic variation and clinical response to antipsychotic drug treatment: a meta-analysis.
The authors conducted the first meta-analysis to examine the relationship between DRD2 polymorphisms and antipsychotic drug response in schizophrenia patients, finding that variation in the DRD(2) gene is associated with clinical response to antipsychotics. Expand
Analysis of microbiota in first episode psychosis identifies preliminary associations with symptom severity and treatment response
The present findings support the involvement of microbiota alterations in psychotic illness and may provide the basis for exploring the benefit of their modulation on treatment response and remission. Expand
Interaction Between Atypical Antipsychotics and the Gut Microbiome in a Bipolar Disease Cohort
Recent findings linking AAP treatment with differences in gut microbiota communities in a human cohort with bipolar disorder (BD) are described. Expand
Separating host and microbiome contributions to drug pharmacokinetics and toxicity
This study provides an experimental and computational strategy to untangle host and microbial contributions to drug metabolism and establishes mouse models that are isogenic except for a single bacterial gene responsible for microbial BRV metabolism. Expand